AstraZeneca Pharma

AstraZeneca that manufactured Covid-19 vaccine 'Covishield', has announced its global withdrawal, days after admitting that the vaccine has rare side effects. It has cited 'commercial reasons' for th

The deal is the latest by AstraZeneca to pledge supply of its vaccine to governments who have scrambled to agree advance purchases of promising coronavirus vaccines

Political opposition from both the UK and the US could derail any attempt at a deal, especially given the backdrop of the Covid-19 outbreak, Citigroup said

The treatment for lymphoma may lessen the severity of respiratory distress by reducing the inflammation caused by the new coronavirus

The combo treatment has been approved in the United States for adult patients with extensive-stage small cell lung cancer, the company said

Sun Pharma has been working out deals through this year to gain foothold in the Chinese market

The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed

AstraZeneca said the transaction won't impact earnings this year but will make a 'significant contribution' by 2023

The announcement follows signing of a bilateral innovation partnership for a sustainable future between Sweden and India, AstraZeneca said in a statement on Tuesday

Drug firm AstraZeneca Pharma has received marketing authorisation from the Drug Controller General of India (DCGI) for Xigduo XR tablets used in treatment of adults with type 2 diabetes in India. The product is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes, AstraZeneca Pharma India said in a statement. The tablet, a product of the AstraZeneca Group, has been approved in 61 countries, including the US, EU and Japan, and demonstrates an overall favourable benefit risk profile for treatment of patients with type 2 diabetes, it added. The company, however, did not share the price at which it would be selling the tablets. "Xigduo XR will provide physicians and patients with an advanced treatment option that provides better glycemic control, potential weight loss and the reduced risk of hypoglycemia," AstraZeneca India Medical Affairs & Regulatory Head Anilda Dsouza said. With these tablets the company is ...

Deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019

The stock, which opened the day on a positive note, gained 6.35 per cent to Rs 1,009 on BSE

Under restructuring company sold-off its antibiotic business to Pfizer in August

The stock was down 6.4% to Rs 1,067, as compared to 0.27% rise in the S&P BSE Sensex at 10:16 am.